Erythroid maturation agents, or EMAs, are a newer treatment option for beta thalassemia. In this video, learn how EMAs work to improve anemia and reduce the risk of complications from beta thalassemia, according to Jonathan Feld, MD, Hematology Specialist at The Mount Sinai Hospital in New York City.
Jonathan Feld, MD, is a hematology specialist at The Mount Sinai Hospital.
References
Bajwa, H., et al. (2022). Thalassemia. StatPearls.
Bristol Myers Squibb. (2022). REBLOZYL [package insert].
Cappellini, M. D., et al. (2021). The use of luspatercept for thalassemia in adults. Blood Advances.
Centers for Disease Control and Prevention. (2025). Treatment of thalassemia.
Rasel, M., et al. (2022). Transfusion iron overload. StatPearls.
Why trust our experts?
Written by:
Lauren Smith, MALauren Smith, MA, has worked in health journalism since 2017. Before joining GoodRx, she was the senior health editor and writer for HealthiNation.
Reviewed by:
Karen Hovav, MD, FAAPKaren Hovav, MD, FAAP, has more than 15 years of experience as an attending pediatrician. She has worked in a large academic center in an urban city, a small community hospital, a private practice, and an urgent care clinic.
